Johnson & Johnson $JNJ Stock Sold by Mechanics Bank Trust Department

Mechanics Bank Trust Department trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 34,202 shares of the company’s stock after selling 2,651 shares during the quarter. Johnson & Johnson makes up approximately 1.2% of Mechanics Bank Trust Department’s holdings, making the stock its 23rd largest position. Mechanics Bank Trust Department’s holdings in Johnson & Johnson were worth $9,055,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Outlook Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter valued at approximately $28,000. Matrix Trust Co grew its stake in Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after purchasing an additional 54 shares during the period. Montgomery Financial Services LLC purchased a new stake in Johnson & Johnson in the second quarter worth $43,000. Hyposwiss Advisors SA bought a new position in Johnson & Johnson in the fourth quarter worth $42,000. Finally, Polaris Financial Partners bought a new position in Johnson & Johnson in the third quarter worth $56,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 5.6%

Shares of Johnson & Johnson stock traded down $14.83 during midday trading on Tuesday, hitting $248.90. The company had a trading volume of 16,613,205 shares, compared to its average volume of 7,994,569. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. The stock has a market capitalization of $599.83 billion, a P/E ratio of 28.84, a P/E/G ratio of 2.65 and a beta of 0.21. The company has a 50 day moving average of $265.89 and a 200 day moving average of $249.37. Johnson & Johnson has a 52-week low of $184.66 and a 52-week high of $281.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.18 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Analyst Ratings Changes

Several brokerages have commented on JNJ. Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. Guggenheim reaffirmed a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a research report on Wednesday, October 7th. Citigroup increased their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 23,054 shares of the firm’s stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 87,569 shares of company stock valued at $23,064,544. Insiders own 0.16% of the company’s stock.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: JNJ reported third-quarter adjusted EPS of $2.59, above the $2.53 analyst consensus, while revenue increased 5.9% year over year to approximately $25.4 billion. Johnson & Johnson Q3 earnings report
• Positive Sentiment: Management raised its 2026 outlook, lifting the reported sales midpoint to $101.2 billion and adjusted EPS midpoint to $11.10, supported by Innovative Medicine growth. Johnson & Johnson raises 2026 guidance
• Positive Sentiment: TREMFYA sales and encouraging long-term Crohn’s disease data provide support for JNJ’s pharmaceutical growth strategy, helping offset pressure from Stelara biosimilar competition. TREMFYA Crohn’s disease data
• Positive Sentiment: The company declared a quarterly dividend of $1.34 per share, reinforcing its appeal to income-focused investors. Johnson & Johnson dividend announcement
• Neutral Sentiment: JNJ said it is leaning toward spinning out its hips-and-knees business, a potential long-term restructuring catalyst but also an acknowledgment of challenges within MedTech. J&J hips-and-knees business spinoff
• Negative Sentiment: MedTech growth disappointed, particularly in cardiovascular and surgery markets outside the United States. Investors viewed the segment’s performance as evidence that the business may require further improvement. Investors focus on J&J MedTech
• Negative Sentiment: Reported net income fell sharply and GAAP EPS declined to $0.09 because of charges tied largely to the proposed talc litigation resolution, the Firefly Bio acquisition and the Sail Biomedicines collaboration. Johnson & Johnson quarterly report analysis
• Negative Sentiment: Investors appeared to treat the guidance increase as modest relative to elevated expectations, while new drug deals are expected to pressure 2027 earnings. Broader healthcare weakness and geopolitical disruption affecting device sales added to the selling pressure.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.